Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Offer $800M in Senior Notes

NEW YORK – PerkinElmer said after the close of the market on Thursday it is offering $800 million in senior notes.

The Waltham, Massachusetts-based firm is offering $400 million aggregate principal amount of 2.550 percent senior notes due 2031 at an issue price of 99.965 percent of the principal amount and $400 million aggregate principal of 3.625 percent senior notes due 2051 at an issue price of 99.999 percent of the principal amount.

The notes will pay on a semi-annual basis, the company said.

PerkinElmer plans to use about $561 million of the net proceeds to repay debt under its senior unsecured revolving credit facility to fund part of its planned $591 million acquisition of Oxford Immunotec. The remaining proceeds will go toward the repayment at maturity of a portion of its outstanding €300 million ($359 million) aggregate principal amount of .600 percent senior notes due 2021.

JP Morgan, Bank of America Securities, and Wells Fargo Securities were the joint book-running managers for the offering, which is expected to close on March 8. 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.